| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
WHO. Available online at: accessed April, 2021.
URL
|
| 3 |
Jiang ZF, Wang M, Xu JL. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer[J]. Life Sci, 2018, 194: 1-6.
|
| 4 |
Zimmerman R, Wahren B, Edsmyr F. Assessment of serial CEA determinations in urine of patients with bladder carcinoma[J]. Cancer, 1980, 46(8): 1802-1809.
|
| 5 |
Zhao M, Liu Y, Liu R, et al. Upregulation of IL-11, an IL-6 family cytokine, promotes tumor progression and correlates with poor prognosis in non-small cell lung cancer[J]. Cell Physiol Biochem, 2018, 45(6): 2213-2224.
|
| 6 |
Smyth MJ, Cretney E, Kershaw MH, et al. Cytokines in cancer immunity and immunotherapy[J]. Immunol Rev, 2004, 202: 275-293.
|
| 7 |
Tang H, Bai Y, Shen W, et al. Clinical significance of combined detection of interleukin-6 and tumour markers in lung cancer[J]. Autoimmunity, 2018, 51(4): 191-198.
|
| 8 |
Naqash AR, Yang LV, Sanderlin EJ, et al. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report[J]. Acta Oncol, 2018, 57(5): 705-708.
|
| 9 |
Pinargote-Celorio H, Miralles G, Cano M, et al. Cytokine levels predict 30-day mortality in octogenarians and nonagenarians with community-acquired pneumonia: a retrospective observational study[J]. Eur J Clin Microbiol Infect Dis, 2020, 39(2): 299-307.
|
| 10 |
Mendez R, Menendez R, Cilloniz C, et al. Initial inflammatory profile in community-acquired pneumonia depends on time since onset of symptoms[J]. Am J Respir Crit Care Med, 2018, 198(3): 370-378.
|
| 11 |
Bazan-Socha S, Mastalerz L, Cybulska A, et al. Prothrombotic state in asthma is related to increased levels of inflammatory cytokines, IL-6 and TNFalpha, in peripheral blood[J]. Inflammation, 2017, 40(4): 1225-1235.
|
| 12 |
Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance[J]. Tumour Biol, 2016, 37(9): 11553-11572.
|
| 13 |
Chu Y, Wang Y, Peng W, et al. STAT3 activation by IL-6 from adipose-derived stem cells promotes endometrial carcinoma proliferation and metastasis[J]. Biochem Biophys Res Commun, 2018, 500(3): 626-631.
|
| 14 |
Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review)[J]. Breast Cancer Res Treat, 2007, 102(2): 129-135.
|
| 15 |
Lin Y, He Z, Ye J, et al. Progress in understanding the IL-6/STAT3 Pathway in Colorectal Cancer[J]. Onco Targets Ther, 2020, 13: 13023-13032.
|
| 16 |
Kucera R, Topolcan O, Treskova I, et al. Evaluation of IL-2, IL-6, IL-8 and IL-10 in malignant melanoma diagnostics[J]. Anticancer Res, 2015, 35(6): 3537-3541.
|
| 17 |
Pan YW, Zhou ZG, Wang M, et al. Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis[J]. Genet Mol Res, 2016, 15(4). doi: 10.4238/gmr15048949. |
| 18 |
Chang CH, Hsiao CF, Yeh YM, et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy[J]. Int J Cancer, 2013, 132(9): 1977-1985.
|
| 19 |
Huang X, Xiao S, Zhu X, et al. miR-196b-5p-mediated downregulation of FAS promotes NSCLC progression by activating IL-6-STAT3 signaling[J]. Cell Death Dis, 2020, 11(9): 785.
|
| 20 |
Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics[J]. Cancer, 2007, 110(9): 1911-1928.
|
| 21 |
Lederle W, Depner S, Schnur S, et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines[J]. Int J Cancer, 2011, 128(12): 2803-2814.
|
| 22 |
Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment [J]. Semin Immunol, 2014, 26(1): 38-47.
|
| 23 |
Loeb LA, Ernster VL, Warner KE, et al. Smoking and lung cancer: an overview[J]. Cancer Res, 1984, 44(12 Pt 1): 5940-5958.
|
| 24 |
Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke[J]. BMJ, 1997, 315(7114): 980-988.
|
| 25 |
Chen PH, Chang H, Chang JT, et al. Aryl hydrocarbon receptor in association with RelA modulates IL-6 expression in non-smoking lung cancer[J]. Oncogene, 2012, 31(20): 2555-2565.
|
| 26 |
Koo JB, Han JS. Cigarette smoke extract-induced interleukin-6 expression is regulated by phospholipase D1 in human bronchial epithelial cells[J]. J Toxicol Sci, 2016, 41(1): 77-89.
|
| 27 |
Xie C, Zhu J, Jiang Y, et al. Sulforaphane inhibits the acquisition of tobacco smoke-induced lung cancer stem cell-like properties via the IL-6/DeltaNp63alpha/Notch Axis[J]. Theranostics, 2019, 9(16): 4827-4840.
|
| 28 |
Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092.
|
| 29 |
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212): 1929-1939.
|
| 30 |
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018-2028.
|